News und Analysen
Better Buy: Abbott Laboratories vs. Intuitive Surgical
Investors looking for stocks that can go up want to turn their heads toward the medical technology industry. Demand for devices that enable minimally invasive surgical procedures and remote
Why AbbVie Stock Was Cruising Higher on Thursday
AbbVie (NYSE: ABBV) stock was the cure for what ails a portfolio on Thursday. The sturdy pharmaceutical company was a favorite of investors, who were trading its shares up by nearly 4% in price in
AbbVie (ABBV) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
AbbVie (NYSE: ABBV)Q2 2024 Earnings CallJul 25, 2024, 9:00 a.m. ET
Operator
Source Fool.com
Is Vertex Pharmaceuticals' Monopoly in Danger?
Over the past decade, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret. The drugmaker developed and marketed
Got $5,000? These 3 Growth Stocks Are Incredibly Cheap Buys Right Now
Buying quality growth stocks doesn't have to involve paying an enormous premium. There are some solid, underrated companies worth buying right now that don't trade at egregious valuations. While
Is AbbVie the Best Dividend Stock for You?
It was great while it lasted, but AbbVie's (NYSE: ABBV) most important cash cow -- rheumatoid arthritis treatment Humira -- has been out of patent exclusivity in the U.S. since last year. That's not
3 High-Yielding Dividend Stocks That Can Help Bankroll Your Retirement Years
If you're looking for some good dividend stocks to own in retirement, one thing you'll want to focus on is stability. Striking a balance between safety and dividend income can be key to ensuring you
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
If you're looking to invest in order to get richer, that's great -- because most of us need to be amassing a war chest for retirement (not to mention other financial goals, such as a down payment
Beware, Wegovy -- Pfizer Is Working on a Competitor
Which company is the leader in the burgeoning weight loss drug market? A recent poll found that among the largest drugmakers, Pfizer (NYSE: PFE) is the one Americans associate most with this
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex Pharmaceuticals (NASDAQ: VRTX) is trading near a record high after climbing about 20% so far this year, and delivering a triple-digit gain over three years. So, you may be a bit hesitant
Humana Healthy Horizons Commits to Increasing Healthcare Access for Oklahomans
Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana Inc. (NYSE: HUM), is investing in community-based organizations throughout Oklahoma to expand access
This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer
If there's one thing healthcare giant Pfizer (NYSE: PFE) really needs right now, it's a compelling growth catalyst. This year, the company isn't expecting much in the way of growth and investors are
This Ultra-High-Yield Dividend Stock Hits Yet Another Setback
Medical Properties Trust (NYSE: MPW) has been struggling because of tenant issues, which has made it more difficult for the real estate investment trust (REIT) to manage its large debt load. The
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
Shares of Big Pharma company AbbVie (NYSE: ABBV) inched higher recently in response to positive news from a Wall Street investment bank. BMO Capital analyst Evan Seigerman raised his price target on
Agilent to Acquire North American CDMO BIOVECTRA
Agilent Technologies Inc. (NYSE: A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss
UnitedHealth Group Rallies Despite Continued Cyberattack Cost Pressures. Is It Too Late to Buy the Stock?
Shares of UnitedHealth Group (NYSE: UNH) were rallying despite a past cyberattack on the company's Change Healthcare business continuing to affect the company's results. But with investors now
Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.
On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage
Abbott Laboratories (ABT) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Abbott Laboratories (NYSE: ABT)Q2 2024 Earnings CallJul 18, 2024, 9:00 a.m. ET
Operator
Source Fool.com
3 Absurdly Cheap Stocks to Buy and Hold for Years
Stocks that are trading at low- and discounted-earnings multiples can sometimes be value traps. But other times, it's just due to short-term and temporary factors that the stocks aren't doing
Why UnitedHealth Stock Rocketed Nearly 7% Higher Today
A convincing bottom-line beat helped increase the share price of big health insurer UnitedHealth Group (NYSE: UNH) on Tuesday. Investors liked what they saw with the company's second-quarter
UnitedHealth Group (UNH) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
UnitedHealth Group (NYSE: UNH)Q2 2024 Earnings CallJul 16, 2024, 8:45 a.m. ET
Operator
Source Fool.com
How Much Will Medtronic Pay Out in Dividends This Year?
Medtronic (NYSE: MDT), a beast of a medical-device company, has caught the eye of more than a few income investors. It has enacted dividend raises at least once annually for a hard-to-beat 47 years
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Vertex Pharmaceuticals (NASDAQ: VRTX) has made it to the major leagues in the world of biotech. The company is the leading maker of cystic fibrosis (CF) treatments, with its products generating more
What Is the Dividend Payout for Amgen Stock?
Can a biotechnology company pay a generous dividend in 2024? The answer is definitely yes, as Amgen (NASDAQ: AMGN) is evidently unafraid to reward its loyal shareholders with quarterly cash